^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    melphalan

    i
    Other names: L-PAM, L-sarcolysin, phenylalanine mustard
    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    2d
    Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders (clinicaltrials.gov)
    P2, N=48, Recruiting, Masonic Cancer Center, University of Minnesota | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Rituxan (rituximab) • cyclophosphamide • Campath (alemtuzumab) • melphalan • fludarabine IV • busulfan
    2d
    NCI-2020-01626: Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis (clinicaltrials.gov)
    P2, N=79, Active, not recruiting, Fred Hutchinson Cancer Center | Recruiting --> Active, not recruiting | N=60 --> 79 | Trial completion date: Dec 2029 --> Apr 2030
    Enrollment closed • Enrollment change • Trial completion date
    |
    Jakafi (ruxolitinib) • cyclophosphamide • methotrexate • melphalan • fludarabine IV • busulfan
    3d
    Monitoring of autologous hematopoietic stem cell transplantation for elderly patients with intermediate and high risk acute myeloid leukemia based on second-generation flow cytometry and digital PCR (ChiCTR2600115992)
    P=N/A, N=20, Not yet recruiting, The First Affiliated Hospital of Xinjiang Medical University; The First Affiliated Hospital of Xinjiang Medical University
    New trial
    |
    Venclexta (venetoclax) • azacitidine • cyclophosphamide • melphalan • busulfan
    3d
    A phase II clinical study evaluating the efficacy and safety of Decitabine combined with Melphalan in newly diagnosed MDS-IB (ChiCTR2500115218)
    P2, N=28, Not yet recruiting, The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
    New P2 trial
    |
    decitabine • melphalan
    3d
    DEMEL-1: A single-center, single-arm, phase II clinical study evaluating the efficacy and safety of Decitabine combined with low-dose Melphalan in patients with high-risk refractory myelodysplastic syndrome (ChiCTR2500115432)
    P2, N=20, Not yet recruiting, The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
    New P2 trial
    |
    decitabine • melphalan
    5d
    SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells (clinicaltrials.gov)
    P1, N=24, Recruiting, General Oncology, Inc. | N=10 --> 24 | Trial completion date: Aug 2027 --> Dec 2028 | Trial primary completion date: Aug 2026 --> Dec 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    HER-2 negative • PALB2 mutation
    |
    carmustine • melphalan • Mustargen (mechlorethamine)
    6d
    Implementation of Natural Products and Derivatives in Acute Myeloid Leukemia Management: Current Treatments, Clinical Trials and Future Directions. (PubMed, Cancers (Basel))
    By targeting nucleic acids, FLT3 or CD33, several FDA-approved NPs and NPDs (i.e., cytarabine, anthracyclines, midostaurin, melphalan and calicheamicin linked to anti-CD33) are the major agents of upfront treatment of AML. This review summarizes the current state of the art, and provides a summary of selected NPs/NPDs which are either entering or have been investigated in preclinical and clinical trials, alone or in combination with current chemotherapy. With multifaceted actions, these biomolecules may target all hallmarks of AML, including multidrug resistance and deregulated metabolism.
    Review • Journal • IO biomarker
    |
    FLT3 (Fms-related tyrosine kinase 3) • BCL2 (B-cell CLL/lymphoma 2) • ANPEP (Alanyl Aminopeptidase, Membrane)
    |
    cytarabine • midostaurin • melphalan
    10d
    Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver (clinicaltrials.gov)
    P=N/A, N=10, Not yet recruiting, Massachusetts General Hospital
    New trial
    |
    melphalan
    11d
    Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin (clinicaltrials.gov)
    P1, N=99, Completed, Children's Oncology Group | Active, not recruiting --> Completed | Trial completion date: Sep 2025 --> Dec 2025
    Trial completion • Trial completion date
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification
    |
    cisplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • busulfan • Azedra (iobenguane I 131)
    11d
    Hyperthermic isolated limb perfusion with TNF-alpha and melphalan for the treatment of locally advanced soft-tissue sarcoma (PubMed, Oper Orthop Traumatol)
    Perfusion of the limb with 1-2 mg recombinant TNF-alpha (Tasonermin/Beromun, Belpharma SA, Luxembourg) for 15 min, followed by the addition of 11-13 mg melphalan per liter of limb volume and subsequent perfusion for an additional 60 min. Complete remissions observed in just under 20% of cases. Limb preservation is possible in over 80% of cases.
    Review • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    melphalan • Beromun (tasonermin)
    11d
    Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes (clinicaltrials.gov)
    P2, N=50, Recruiting, Fred Hutchinson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Jakafi (ruxolitinib) • cyclophosphamide • methotrexate • melphalan • fludarabine IV • busulfan • methotrexate IV
    12d
    GEM-BELA-VRd: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, PETHEMA Foundation | Trial completion date: Dec 2025 --> Jun 2026
    Trial completion date
    |
    lenalidomide • bortezomib • dexamethasone • melphalan • Blenrep (belantamab mafodotin-blmf)